FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received acce

Source: FDA Center for Drug Evaluation and Research - What's New - April 29, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news